What is the difference between germline and somatic testing for Triple-Negative Breast Cancer

Germline vs. Somatic Testing for Triple-Negative Breast Cancer

This is an excellent question, especially for triple-negative breast cancer (TNBC), where understanding your genetic mutations can directly impact treatment decisions.

The Key Difference

Germline mutations are changes in your DNA that you're born with—they're present in every cell in your body, including your cancer cells. You inherited them from one or both parents.

Somatic mutations are changes that occur only in your cancer cells during your lifetime. They're not inherited and aren't present in your normal cells.

Why This Matters for TNBC Treatment

According to expert guidance from CancerPatientLab webinars, somatic mutations take priority for treatment decisions because they're what's actually driving your specific tumor. As pathologist Tony Magliocco explains: "You're trying to kill the tumor. The somatic has priority in the tumor. You always go with somatic in the tumor."

Here's a practical example: You might have a germline BRCA mutation (inherited predisposition), but if your tumor's somatic testing doesn't show BRCA loss, your cancer may not actually have the characteristics that make it responsive to PARP inhibitors. Your doctor needs to know what's happening in your tumor specifically.

What Each Test Tells You

| Germline Testing | Somatic Testing | |---|---| | Tests your inherited DNA | Tests only your tumor's DNA | | Affects cancer risk for you AND relatives | Specific to your current cancer | | Guides screening for other cancers | Guides treatment for THIS cancer | | Informs family planning decisions | Identifies actionable mutations in tumor | | Example: BRCA1/2 mutations | Example: BRCA loss in tumor, TP53 mutations |

For Triple-Negative Breast Cancer Specifically

TNBC is particularly important to test thoroughly because:

• BRCA mutations (germline or somatic) are more common in TNBC and may make you eligible for PARP inhibitors
• Somatic testing can reveal other mutations that guide immunotherapy or targeted therapy options
• Whole genome/exome sequencing may find actionable mutations that standard tests miss

As Dr. [removed] Lopez-Correa (an MD with breast cancer experience) noted, standard tests like Oncotype DX provide a score but don't give you detailed mutation information. Whole exome sequencing of your tumor tissue can reveal mutations that aren't captured in routine testing—mutations that might be critical for treatment decisions.

Questions to Ask Your Oncologist

1. Have I had somatic (tumor) testing done? If so, what actionable mutations were found?
2. Should I have germline testing? This helps determine if you have inherited cancer predisposition.
3. If I have a BRCA mutation, is it germline or somatic in my tumor? This affects which treatments might work.
4. Are there other mutations in my tumor that could guide treatment? (TP53, PTEN, PIK3CA, etc.)
5. Do I need genetic counseling to understand what my results mean for my family?

Important Context

Genetic counseling is strongly recommended, especially if you have germline mutations. As the experts emphasize, just because you carry a mutation doesn't mean you'll definitely develop cancer—mutations have different penetrances (likelihood of causing disease), and they interact with other factors.

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.